Journal: Nature Communications

Article Title: Hypoxia induced responses are reflected in the stromal proteome of breast cancer

doi: 10.1038/s41467-023-39287-7

Figure Lengend Snippet: Multivariate survival analysis (proportional hazards regression model) of breast cancer patients (METABRIC-Discovery cohort)

Article Snippet: Of relevance for secretome studies, we found that 40 of the PAM50 signature genes/proteins have been reported in serum or plasma (plasma proteome database; PPD: http://www.plasmaproteomedatabase.org/ ) , and/or the Human Protein Atlas—blood protein (Human Protein Atlas proteinatlas.org) .

Techniques:

Journal: Appetite

Article Title: Acute responses to opioidergic blockade as a biomarker of hedonic eating among obese women enrolled in a mindfulness-based weight loss intervention trial

doi: 10.1016/j.appet.2015.04.062

Figure Lengend Snippet: Naltrexone-induced cortisol increases from 1 PM to 4 PM on placebo and naltrexone days at baseline.

Article Snippet: Materials & Measures Study drug We instructed participants to orally ingest 50 mg of naltrexone hydrochloride (ReVia; Teva, North Wales, PA), the FDA-approved dose for treatment of alcohol and opioid dependence, or an identical-looking placebo pill.

Techniques:

Journal: Appetite

Article Title: Acute responses to opioidergic blockade as a biomarker of hedonic eating among obese women enrolled in a mindfulness-based weight loss intervention trial

doi: 10.1016/j.appet.2015.04.062

Figure Lengend Snippet: Treatment arm (mindfulness vs. active control) × baseline naltrexone-induced Cortisol (4 PM – 1 PM) predicting weight and self-report hedonic eating measures at 6 months ( N =88).

Article Snippet: Materials & Measures Study drug We instructed participants to orally ingest 50 mg of naltrexone hydrochloride (ReVia; Teva, North Wales, PA), the FDA-approved dose for treatment of alcohol and opioid dependence, or an identical-looking placebo pill.

Techniques: Control

Journal: Appetite

Article Title: Acute responses to opioidergic blockade as a biomarker of hedonic eating among obese women enrolled in a mindfulness-based weight loss intervention trial

doi: 10.1016/j.appet.2015.04.062

Figure Lengend Snippet: Interaction of naltrexone-induced cortisol response and treatment arm (active control vs. mindfulness) as a predictor of changes in self-reported food addiction symptoms.

Article Snippet: Materials & Measures Study drug We instructed participants to orally ingest 50 mg of naltrexone hydrochloride (ReVia; Teva, North Wales, PA), the FDA-approved dose for treatment of alcohol and opioid dependence, or an identical-looking placebo pill.

Techniques: Control

Journal: Appetite

Article Title: Acute responses to opioidergic blockade as a biomarker of hedonic eating among obese women enrolled in a mindfulness-based weight loss intervention trial

doi: 10.1016/j.appet.2015.04.062

Figure Lengend Snippet: Means and standard deviations of baseline weight, self-report eating measures, and naltrexone-induced cortisol response by nausea group ( N =88).

Article Snippet: Materials & Measures Study drug We instructed participants to orally ingest 50 mg of naltrexone hydrochloride (ReVia; Teva, North Wales, PA), the FDA-approved dose for treatment of alcohol and opioid dependence, or an identical-looking placebo pill.

Techniques:

Journal: Appetite

Article Title: Acute responses to opioidergic blockade as a biomarker of hedonic eating among obese women enrolled in a mindfulness-based weight loss intervention trial

doi: 10.1016/j.appet.2015.04.062

Figure Lengend Snippet: Interaction of naltrexone-induced nausea (present vs. absent) and treatment arm (active control vs. mindfulness) as a predictor of changes in self-report measures of food addiction and binge eating symptoms.

Article Snippet: Materials & Measures Study drug We instructed participants to orally ingest 50 mg of naltrexone hydrochloride (ReVia; Teva, North Wales, PA), the FDA-approved dose for treatment of alcohol and opioid dependence, or an identical-looking placebo pill.

Techniques: Control

Journal: Appetite

Article Title: Acute responses to opioidergic blockade as a biomarker of hedonic eating among obese women enrolled in a mindfulness-based weight loss intervention trial

doi: 10.1016/j.appet.2015.04.062

Figure Lengend Snippet: Treatment arm (mindfulness vs. active control) × baseline naltrexone-induced nausea (present vs. absent) predicting weight and self-report hedonic eating measures at 6 months ( N =88).

Article Snippet: Materials & Measures Study drug We instructed participants to orally ingest 50 mg of naltrexone hydrochloride (ReVia; Teva, North Wales, PA), the FDA-approved dose for treatment of alcohol and opioid dependence, or an identical-looking placebo pill.

Techniques: Control

Journal: Appetite

Article Title: Acute responses to opioidergic blockade as a biomarker of hedonic eating among obese women enrolled in a mindfulness-based weight loss intervention trial

doi: 10.1016/j.appet.2015.04.062

Figure Lengend Snippet: Naltrexone sub-study participant characteristics, N =88.

Article Snippet: Materials & Measures Study drug We instructed participants to orally ingest 50 mg of naltrexone hydrochloride (ReVia; Teva, North Wales, PA), the FDA-approved dose for treatment of alcohol and opioid dependence, or an identical-looking placebo pill.

Techniques: Control